Besides, the IFI44L promoter methylation level may also be a potential biomarker of disease activity of SLE, because this gene promoter exhibit significantly increased methylation level in lupus patients in remission stage than in active stage. The gene discussed is IFI44L; the disease is systemic lupus erythematosus.